Akademik Veri Yönetim Sistemi
Eurasian Journal of Medical Investigation, cilt.6, sa.2, ss.180-183, 2022 (Hakemli Dergi)
Objectives: Neuropathy is one of the most common side effects in the treatment of paclitaxel. Neuropathy, which develops with the treatment of paclitaxel, cisplatin, and oxaliplatin, is a limiting factor in the treatment and may lead to the termination of the patient's treatment. The metabolic consequences of chemotherapy have not been extensively studied. It is known that insulin resistance and hyperglycemia develop in a subgroup of patients. Triglyceride Glucose index (TyG) index is used as an insulin resistance marker. In our study, we aimed to examine the relationship between insulin resistance and neuropathic pain due to paclitaxel chemotherapy. Methods: The blood lipid profile, hemagram profile and biochemical parameters routinely checked from the histopathologically diagnosed cases over 18 years of age were scanned and recorded between 06.01.2017 - 09.01.2021. Before the first chemotherapy, before the third month of chemotherapy, serum glucose, high-density lipoprotein, lowdensity lipoprotein in patients who developed neuropathic pain within 3 months and did not develop neuropathic pain in patients who underwent paclitaxel (paclitaxel 80 mg / m2 12 weeks 1 per week) chemotherapy protocol due to cancer diagnosis. , triglyceride, total cholesterol and hemogram parameters were recorded by retrospective file scanning method. Triglyceride glucose index (TyG index (mg/dl)) = ln [fasting triglyceride (mg/dl) x fasting blood glucose (mg/dl) /2] Calculated TyG index 4.49 and higher was evaluated as insulin resistance Neuropathy pain score was calculated with the DN4 neuropathic pain questionnaire, which is a validated test. Results: In our study, we found that the TyG index was higher in patients who developed neuropathic pain before paclitaxel treatment was started, compared to those who did not develop neuropathic pain. Conclusion: We believe that more comprehensive studies are needed by increasing the number of patients on the etiopathogenesis of the neuropathy development mechanism